#version: 0.2
i n
t i
r e
t h
a n
e n
e r
e d</w>
o n
o f</w>
a t
r o
i n</w>
th e</w>
i t
a ti
a r
an d</w>
o n</w>
s i
a l
s t
a l</w>
o r
i c
a s
d i
e c
en t
a c
l o
in g</w>
d e
o r</w>
a s</w>
u r
t o</w>
e r</w>
w it
u l
wit h</w>
s e
o m
a m
o l
u c
e s
re s
o c
l y</w>
in e</w>
l e
en t</w>
p h
p ro
o u
p ati
c on
r i
w as</w>
d uc
ati on</w>
T h
er e</w>
v e</w>
i d
e s</w>
at ed</w>
a d
o s
v e
s .</w>
h e
p er
f f
a t</w>
i s</w>
a n</w>
i c</w>
m e
o t
a g
a p
i l
w ere</w>
ent s</w>
u s
c h
c e
i m
duc ed</w>
ti on</w>
i s
a b
t re
h y
t er
c om
t r
f or</w>
Th e</w>
p a
s u
n e
in e
o x
ec t
b y</w>
u n
pati ents</w>
e x
in duced</w>
b e
p l
re n
v er
e ff
ati on
in c
w e
e n</w>
r at
h i
a r</w>
it y</w>
m ent</w>
t er</w>
s ,</w>
p res
re as
a f
re d</w>
c ar
i f
m in
th at</w>
u t
h a
n o
c e</w>
s y
ti on
o p
g n
l i
t e
0 .
u d
l e</w>
r a
- induced</w>
m a
an t
ti c</w>
af ter</w>
tre at
m o
y .</w>
p re
v i
w h
g /
i st
at e</w>
ro u
p t
e m
th er
p or
con t
ti ve</w>
i z
u m
si on</w>
q u
ic al</w>
c l
) .</w>
e p
si gn
as e</w>
an t</w>
d o
ul ar</w>
c o
r u
m on
p o
th e
d a
b e</w>
e t
h o
u m</w>
on e</w>
g h
ur e</w>
ou s</w>
p ar
in f
d .</w>
os e</w>
re ce
i r
inc reas
no t</w>
if ic
car di
ther ap
s er
m g/
ect s</w>
an ti
treat ment</w>
g rou
res p
si s</w>
an g
sign ific
th er</w>
) ,</w>
or m
y ,</w>
e l
v ed</w>
g en
ent r
in g
i a</w>
b u
s e</w>
ar y</w>
lo w
m ic
d ru
u re
min ist
y l
hy per
ti v
c or
m or
as s
ad minist
e v
oc i
c a
ro m</w>
en ce</w>
I n</w>
t en
lo g
si on
d ur
f rom</w>
s p
o b
al ly</w>
e .</w>
re l
ti c
u ro
ass oci
lo p
u s</w>
S :</w>
pa th
eff ec
di s
th is</w>
t a
st ud
e ar
in d
eff ects</w>
re por
ar e</w>
es e</w>
tr a
b lo
us e</w>
de ve
p ot
tre ated</w>
ha d</w>
i d</w>
oc a
t ed</w>
ox ic
d ose</w>
O N
ve l
a z
t s</w>
d er
s ho
i o
deve lop
e st
ro m
th an</w>
associ ated</w>
e ,</w>
mg/ k
i th
se s</w>
su b
ti m
c ur
ac tiv
dur ing</w>
+ /
0. 0
f ol
f i
ou n
ation s</w>
cont ro
bu t</w>
m y
s c
o l</w>
resp on
ut e</w>
in j
id e</w>
ne uro
or y</w>
c y
o log
un c
l l
pot en
w ith
r an
administ r
rece i
ma y</w>
d ec
us ed</w>
v en
res ul
effec t</w>
pati ent
am ine</w>
i ti
rat s</w>
l l</w>
m ent
ren al</w>
stud y</w>
g h</w>
pati ent</w>
( 1
in ed</w>
p os
W e</w>
b o
o d</w>
ff e
en d
an c
in ter
i a
ati ve</w>
d ,</w>
be en</w>
tr an
v er</w>
+/ -</w>
therap y</w>
da y
t oxic
d y
ar di
grou p
n orm
si ve</w>
ag e</w>
es s</w>
ac t
signific ant
hi b
pres s
r on
c oca
d e</w>
fol low
es t</w>
we e
ha ve</w>
f unc
es .</w>
increas ed</w>
w he
com p
al l</w>
ation .</w>
be t
a il
al u
p i
f l
dec reas
sy n
significant ly</w>
0 0</w>
ot h</w>
ch ang
se iz
- 1
c entr
g g
u b
wh o</w>
cl in
me th
t w
l on
y ear
g i
mic ro
dru g
le vel
ac ute</w>
ic h</w>
en c
an ce</w>
administr ation</w>
n o</w>
wh ich</w>
v as
in tra
in v
at e
rece pt
ec h
su gg
am in
u di
( 2
ri s
in hib
or s</w>
grou p</w>
ag on
he m
ou t</w>
he ar
s t</w>
ffe ren
h as</w>
t ri
ab le</w>
re e</w>
f ail
id ence</w>
sho w
hi gh
di se
g l
signific ant</w>
gh t</w>
ob ser
s o</w>
p e
st udi
ve n</w>
cardi a
th ese</w>
S I
g r
d ro
g ra
dru g</w>
we en</w>
ec tion</w>
blo od</w>
develop ed</w>
bet ween</w>
re qu
ou r</w>
m pt
c ase</w>
oc ardi
an al
ul d</w>
v entr
di fferen
b oth</w>
ec tive</w>
pro te
Th is</w>
activ ity</w>
st r
me di
tran s
pa red</w>
al so</w>
s en
ine -induced</w>
sy st
wee k
de p
ventr ic
ine .</w>
f orm
f or
al l
si b
oc cur
1 .
b r
tion s</w>
i al</w>
re at
tw o</w>
ect ed</w>
rel ated</w>
o ther</w>
ure s</w>
c as
ine ,</w>
it s</w>
rat e</w>
clin ical</w>
i t</w>
m a</w>
ph en
de r</w>
d ic
com pared</w>
s ec
re c
tion .</w>
in u
ti al</w>
iz ed</w>
m an
lon g
m il
5 -
C L
mpt om
e th
es ,</w>
level s</w>
er g
tr ac
f ir
al s</w>
pl ic
n on
cardia c</w>
M E
mor e</w>
ventric ular</w>
cont inu
a st
i de
m g</w>
g e
mg/k g
t o
ol d</w>
v ing</w>
coca ine</w>
ver ,</w>
al o
p ri
SI ON
% )</w>
a in
u sion</w>
te st
lo w</w>
c lo
duc tion</w>
con centr
y p
hyper ten
R E
hear t</w>
ar i
ar ter
per i
S U
pl as
0 0
he pati
mo de
ev alu
c al
er al</w>
ec ti
d om
s ur
c ular</w>
increas e</w>
do ses</w>
si a</w>
resul ts</w>
contro l</w>
ris k</w>
C ON
se s
dep end
ep i
ou s
di d</w>
CL U
CON CLU
ti s</w>
CONCLU SION
sy mptom
m i
e -
si st
ne ph
Th ese</w>
b l
ver se</w>
se v
mon th
th i
A C
n it
re g
ch ol
an im
day s</w>
rat s.</w>
i .
y c
he mo
inc l
ch ron
com b
es the
show ed</w>
m al
recei ved</w>
treat ment
le p
ech an
blo c
do se
L T
a x
inhib it
ti g
toxic ity</w>
l ess</w>
si de</w>
my ocardi
m at
le v
u e</w>
l at
dy s
c i
il e</w>
norm al</w>
I n
su p
da y</w>
m echan
o ph
ation ,</w>
T H
it y.</w>
hy poten
follow ing</w>
path y</w>
press ure</w>
s ti
th rom
5 0</w>
ant agon
obser ved</w>
sev ere</w>
e i
2 .
func tion</w>
respon se</w>
is o
u se
T I
hi st
ac tion</w>
li ver</w>
mg/k g</w>
ven ous</w>
b as
an e
oun d</w>
ul ation</w>
o di
de ter
ar k
hy th
e d.</w>
v al
pa in</w>
incl ud
r hyth
oc y
v ul
we ver,</w>
SU LT
e d
at ing</w>
RE SULT
me as
or al</w>
de f
pl ac
an d
in al</w>
repor ted</w>
t ac
RESULT S:</w>
gra ph
ol y
po st
O D
chang es</w>
1 0</w>
il ity</w>
repor t</w>
tion ,</w>
s uc
chron ic</w>
f e
sib le</w>
recept or</w>
ri b
whe n</w>
se l
il l
us ing</w>
os t</w>
on ly</w>
d op
ind ic
k e</w>
ser um</w>
f act
m us
es tig
ic in</w>
ine -
e red</w>
t ro
comp le
' s</w>
l im
er s</w>
me an</w>
inv estig
m un
per id
myocardi al</w>
in .</w>
ME TH
pres sion</w>
l it
y m
olog ical</w>
ati c</w>
vas cular</w>
pres ent</w>
erg ic</w>
fail ure</w>
neph ro
in ,</w>
ar c
as ses
w e</w>
ous ly</w>
ad verse</w>
con vul
h or
hy dro
b ra
os ph
1 0
s ed</w>
5 %</w>
with out</w>
ce ll
t h</w>
th ree</w>
un der
bloc k
METH OD
decreas ed</w>
therap y.</w>
fi b
per io
- old</w>
y -
pro t
st er
c an</w>
th ou
in -
mechan is
p it
me t
fir st</w>
anal y
inc idence</w>
for e</w>
at ri
2 -
f requ
epi lep
E C
g lo
resp ecti
ex pos
ia .</w>
ph osph
v ari
gi ven</w>
cas es</w>
re duced</w>
w om
ab ol
tim e</w>
( P
i l</w>
a .</w>
inj ection</w>
b i
ver y</w>
d at
sugg est</w>
ad e</w>
u al</w>
sion .</w>
ar rhyth
recei ving</w>
d rom
i r</w>
m ost</w>
tion al</w>
si s.</w>
d ue</w>
u p
c at
3 .
patient s.</w>
administ ered</w>
s tim
al ph
de sc
si mil
hi gh</w>
ect ro
inf l
sen si
n er
t ing</w>
plas ma</w>
com plic
dise ase</w>
p at
in iti
ar g
im mun
comb in
as t</w>
re f
seiz ures</w>
plac e
en z
syn drom
f ound</w>
s y</w>
b le
im pro
ha vi
p r
em ia</w>
T o</w>
fl u
th ose</w>
pre vi
sion s</w>
respecti vel
hy po
ocy t
ac et
sec on
ia ,</w>
( A
an esthe
s )</w>
sho uld</w>
m it
t ot
H o
sp ec
f ind
o re
METHOD S:</w>
m ac
2 0</w>
sugg est
ent ed</w>
thou gh</w>
c ap
m er
s al
ma in
sy ch
( C
ca used</w>
sub j
h alo
year -old</w>
x im
il d
high er</w>
cardi o
we ll</w>
contro l
syst em
d ox
be havi
eff ect
com m
inf usion</w>
enc y</w>
ing s</w>
P A
intra venous</w>
duc e</w>
se qu
depend ent</w>
a ff
ei ther</w>
ent ly</w>
ad ren
per im
ce ll</w>
dise as
occur red</w>
t yp
c anc
sion ,</w>
gen er
mic e</w>
week s</w>
on ary</w>
a y
syndrom e</w>
symptom s</w>
studi es</w>
o gen
it e</w>
m ark
or ub
3 0</w>
ac id</w>
d am
simil ar</w>
the ir</w>
am p
p sych
gr am
de mon
be fore</w>
ve l</w>
re co
ou t
el ectro
ad di
d s</w>
( P</w>
h e</w>
d ra
re ac
group s</w>
pro g
si de
p er</w>
Ho wever,</w>
ran dom
norm al
no w
ce re
develop ment</w>
CONCLUSION S:</w>
bra in</w>
di ag
s om
com par
k g
C A
f t</w>
ve ly</w>
po si
en ti
e m</w>
r h
es s
in -induced</w>
at al</w>
ec t</w>
k now
A l
ne ur
lo s
drug s</w>
ic i
a ,</w>
vi e
V E
a v
k e
m ul
1 9
3 -
pro duced</w>
o ver</w>
k ine
dra w
4 -
cor onary</w>
dis continu
re ver
t ol
k ing</w>
dat a</w>
met abol
d ed</w>
en ce
m s</w>
5 0
ol e</w>
cur ren
ter m</w>
p ine</w>
ex perim
U N
m ia</w>
c hem
treatment .</w>
per form
mor ph
c ul
decreas e</w>
st at
combin ation</w>
ph y
inv ol
tot al</w>
c hemo
ure .</w>
o ver
month s</w>
in to</w>
am ide</w>
ch ild
R O
ox y
n ec
be ta
dis or
with in</w>
it y,</w>
t ox
se ver
m in</w>
ar ac
r ang
c le
low er</w>
ab ility</w>
e d,</w>
b ut
re t
um b
ti s
ro le</w>
dox orub
pre v
b ec
anim als</w>
with draw
ac h</w>
tol er
s ul
hypoten sion</w>
di st
L -
we i
suc h</w>
is t</w>
y o
4 .
i ly</w>
wh ile</w>
cardi a</w>
0.0 0
trans pl
non -
am ph
g reat
por t
r ine</w>
v alu
v al</w>
id ine</w>
ot or</w>
r at</w>
e lev
on e
( 3
u red</w>
mode l</w>
ca use</w>
1 2</w>
lo c
I t</w>
ol ic</w>
l or
ic ac
m is
ox id
mg/ m
e u
me dic
Th ere</w>
% ,</w>
br al</w>
u res
pi lo
s on
ic ally</w>
ho ur
find ings</w>
re gi
ra di
ane ous</w>
effec tive</w>
ex c
I I
v id
ar mac
f our</w>
c le</w>
th ere</w>
) -
A f
et y</w>
i p
le ft</w>
tac hy
z ed</w>
throm bo
h um
i es</w>
o per
M A
u r</w>
az ep
op en
sur g
at es</w>
uc le
t ub
dose -
o id
al e</w>
cy clo
1 -
e re
v ol
do g
t um
olog ic</w>
re as</w>
de s</w>
cat al
se t</w>
con cl
an y</w>
t e</w>
re ve
dy n
al ed</w>
ot oxic
i red</w>
5 .
eff icac
patient s,</w>
ur al</w>
d ing</w>
ent al</w>
pro long
- term</w>
a y</w>
u p</w>
d os
inf arc
re vie
m ents</w>
( S
K G
ant s</w>
halo perid
( 0.
le vel</w>
alph a
T w
concentr ations</w>
anc ed</w>
hepati c</w>
m ic</w>
1 5</w>
s af
ex peri
mode l
arter ial</w>
differen t</w>
is h
- dose</w>
v it
con di
B AC
s ing
a use</w>
RO UN
KG ROUN
BAC KGROUN
2 4</w>
da ily</w>
ap pro
meth yl
co uld</w>
c in
m ol
k in
A n
m ine</w>
prog res
pilo car
inj ur
at ory</w>
li thi
de t
arac ter
e tic</w>
y l</w>
poten tial</w>
s odi
ag ain
great er</w>
pe a
inj ec
micro gram
ing .</w>
p ac
an e</w>
O B
si s,</w>
re duction</w>
J EC
A N
ph eral</w>
d ul
Af ter</w>
im pa
ex am
pro p
bas el
again st</w>
c ol
u l</w>
in ary</w>
g en</w>
ar b
en s
0.0 5
hyperten sion</w>
ch aracter
stim ul
s a
ing ,</w>
l ab
. )</w>
l ine</w>
includ ing</w>
car b
f em
7 .
TI VE
bo d
OB JEC
o id</w>
al ter
l in
di ab
oca ine</w>
amph et
studi ed</w>
g o
OBJEC TIVE
at ten
is chem
glo mer
ad y
neur on
co ur
w ar
1 )</w>
p ul
6 -
hepati tis</w>
lo l</w>
dop amine</w>
ph armac
ur ther</w>
phy si
i ous</w>
2 0
mg/kg )</w>
6 .
( p</w>
ev idence</w>
on g</w>
i tion</w>
on ic</w>
am e</w>
o graph
p p
nit ro
reve aled</w>
pos sible</w>
n umb
BACKGROUN D
str uc
ro p
r ac
on set</w>
e ach</w>
ve ment</w>
year s</w>
prote in</w>
al ,</w>
meas ured</w>
ate ly</w>
am e
os pit
cell s</w>
beta -
prote in
pri m
en h
peri pheral</w>
centr al</w>
infl am
bod y</w>
l id
us ,</w>
N T
mon it
O n
br ady
1 ).</w>
follow ed</w>
dur ation</w>
yc in</w>
th al
iti es</w>
comm on</w>
S E
BACKGROUND :</w>
mal e</w>
th rou
l if
im port
ent an
A d
ac ti
p y
vi r
ch lor
catal ep
it ed</w>
v ac
tic s</w>
P ati
n a
o f
ll ed</w>
on t
perform ed</w>
G rou
ap p
seiz ure</w>
eu tic</w>
n ic
ad en
4 0</w>
antagon ist
A ll</w>
id enti
sodi um</w>
ri c</w>
( n</w>
poten ti
tic al</w>
s m
previ ously</w>
posi tive</w>
ad ul
c um
CONCLUSION :</w>
f low</w>
a in</w>
re ,</w>
po in
whe ther</w>
A D
Al though</w>
f ul
efficac y</w>
ge si
de x
evalu ated</w>
o d
ine ph
concentr ation</w>
chol est
wee k</w>
fl ur
t ly</w>
is m</w>
ta ined</w>
therap eutic</w>
1 ,</w>
N A</w>
y e
ma j
s ol
di vid
mg/kg ,</w>
mus cle</w>
he mor
b il
cere bral</w>
a d</w>
6 0</w>
he pat
re n</w>
l y
p oly
canc er</w>
curren t</w>
str ated</w>
c es</w>
pro po
ur ia</w>
hemor rh
enz ym
desc ri
A B
mic e.</w>
c is
stat us</w>
le u
secon d
n i
know n</w>
cardi om
cal ci
- treated</w>
ar ly</w>
an s</w>
pl e</w>
par tic
ce p
om a</w>
2 5</w>
perio d</w>
expos ure</w>
t .</w>
re duc
re cor
( N
ex pression</w>
an a
tiv ity</w>
st res
throm b
t est</w>
ear ly</w>
i. p
f en
ati n</w>
an ce
som e</w>
h ospit
ish ed</w>
child ren</w>
2 ,</w>
tox ic</w>
path y.</w>
s /
deter mine</w>
9 5%</w>
dyn am
typ e</w>
sing le</w>
r am
syst em</w>
id ne
Pati ents</w>
al .</w>
te m
k ed</w>
c oun
f ac
d ou
anti -
r ati
8 .
s hor
deter min
( D
basel ine</w>
s us
o st
S )</w>
( H
respon ses</w>
a ined</w>
demon strated</w>
az ol
hyper al
N o</w>
er .</w>
diag no
withdraw al</w>
enc ed</w>
los s</w>
con sist
N e
leu k
ac id
f urther</w>
1 00</w>
c ent
in ine</w>
numb er</w>
long -term</w>
whe reas</w>
al y
C h
z ap
oc amp
analy sis</w>
pri or</w>
ab normal
hi pp
en e
u tion</w>
mon ary</w>
l y,</w>
lit er
recept ors</w>
k idne
fi ed</w>
subj ects</w>
b o</w>
disor der
cardio vascular</w>
gl ut
m g
psych o
c ess
asses sed</w>
( 4
a th
si x</w>
i. v
c it
c er
P )</w>
seiz ures
I I</w>
re sist
P ro
pro duc
place bo</w>
hipp ocamp
de l
as si
di rec
chang e</w>
ation s.</w>
transpl ant
fi ve</w>
diseas e.</w>
bec ause</w>
convul s
al ity</w>
A c
system ic</w>
el l
includ ed</w>
A )</w>
ur inary</w>
nic ot
fact ors</w>
ep iso
ence ph
ac tive</w>
st ar
OBJECTIVE :</w>
r ap
oc h
c reat
in trac
i v
s hi
s :</w>
on e.</w>
in ten
( M
re le
mul ti
respectivel y.</w>
medi an</w>
pro b
A T
ad v
or ph
gl yc
exam ined</w>
0 %</w>
differen ces</w>
se en</w>
S T
surg er
sel ective</w>
rib ed</w>
olog y</w>
t ,</w>
stud y.</w>
ro s
he par
sur vi
e de
st ro
am ong</w>
R e
pro st
hour s</w>
hist ory</w>
hum an</w>
st ri
increas es</w>
mechanis m</w>
investig ated</w>
ti es</w>
prote ren
indic ate</w>
A M
tis su
in duc
f er
app ear
sub st
doxorub icin</w>
p ir
inf u
C om
u lo
ang io
ud e</w>
o -
min ut
bl ad
arter y</w>
w or
5 ,</w>
me n</w>
f entan
0 -
ge sia</w>
Grou p</w>
li ke</w>
- 1</w>
sensi tivity</w>
a u
sp inal</w>
cardiom yo
he ad
is ol
a w
oper ative</w>
prolong ed</w>
m m
he al
2 )</w>
resul ted</w>
sp ont
lithi um</w>
hyperten sive</w>
r it
ol -induced</w>
c ir
m en
experim ental</w>
su s</w>
ne w</w>
f ul</w>
atten u
ag e
A I
ren ce</w>
pres ented</w>
if ic</w>
- bl
otoxic ity</w>
chemo therapy</w>
l as
iz ation</w>
e l</w>
dys kine
ma xim
wom en</w>
liter at
medi ated</w>
gl uc
hydro x
f ol</w>
p le
ner v
f ic
8 -
second ary</w>
am ide
pres ent
re s</w>
pro f
contro lled</w>
e ti
E ff
% ),</w>
wei ght</w>
j u
mechanis ms</w>
sc op
ag ent</w>
maj or</w>
de press
ab s
ver sus</w>
cl on
G AB
iti s</w>
ev ents</w>
ag ent
the li
throu gh</w>
import ant</w>
calci um</w>
rat es</w>
spec ific</w>
n ucle
a ut
I C
dou ble
re st
bi op
in duction</w>
ro sis</w>
ate d.</w>
A t</w>
% ).</w>
dro me
cap sa
arrhyth mi
i ed</w>
dis c
ti co
pres su
le s</w>
am eth
frequ ency</w>
car cin
atri c</w>
ra z
syn drome
inhib ition</w>
m otor</w>
lo ro
associ ation</w>
en do
Tw o</w>
iso proteren
group s.</w>
v is
prim ary</w>
en g
dys function</w>
toxic ity.</w>
P re
ox ide</w>
N -
head ac
neuro pathy</w>
D E
s ame</w>
ster oid
p op
hem at
a k
1 4
inflam mat
cy t
pa m</w>
fem ale</w>
di ff
n ot
( E
tachy cardia</w>
ic e</w>
un der</w>
wom an</w>
ar d</w>
elev ated</w>
H B
a si
vac a
n ess</w>
er ,</w>
ati s
ab l
st and
o ro
infl u
m .</w>
alpha -
cyclo phosph
ab ly</w>
arb it
1 4</w>
ti s.</w>
pl us</w>
inflammat ory</w>
lid ocaine</w>
k al
tran si
pi vaca
comple te</w>
fib ri
con trac
con side
t al</w>
con f
res ol
experi enced</w>
ph ase</w>
or s.</w>
g u
P O
sup por
pul monary</w>
pre treatment</w>
differen ce</w>
ain ing</w>
l arg
m l
convuls ant</w>
ti l
impa ir
glo b
b ol
al one</w>
lit ax
i gn
o m</w>
k et
ag ents</w>
on i
neuro log
ta king</w>
s ;</w>
o lol</w>
1 3
u ally</w>
propo fol</w>
fibri ll
e qu
double -bl
ur ine</w>
tri al</w>
re ma
m m</w>
n ing</w>
rat s,</w>
d oc
antagon ist</w>
C on
on e,</w>
oc c
dam age</w>
9 .
repor ts</w>
o sis</w>
gr ade</w>
injur y</w>
random ized</w>
M D
place bo
in duce</w>
( -1
m b
( T
inj ected</w>
ho wever,</w>
u ses</w>
sub sequ
pres ence</w>
e pam</w>
agon ist
stim ulation</w>
S t
blad der</w>
at eral</w>
5- H
f o
u s.</w>
out com
1 2
v s</w>
c ut
x i
ac in</w>
O ur</w>
e ven</w>
diagno sis</w>
show n</w>
stud y,</w>
m ag
de g
administr ation.</w>
+/ -
res h
dynam ic</w>
dog s</w>
an emia</w>
sever al</w>
7 -
se d
ation shi
p ent
gen ic</w>
cour se</w>
amphet amine</w>
re tion</w>
hy p
C I
treatment ,</w>
ex amin
in d</w>
fail ure.</w>
n os
struc t
ot on
t y</w>
stres s</w>
ogen e
enceph alo
con tr
b ac
s in
re pe
p en
b enz
sal ine</w>
s ).</w>
D -
s o
py ri
pre dic
per f
tic ally</w>
secon d</w>
m id
infarc tion</w>
group .</w>
a re
A n</w>
follow -
1 1</w>
ye ar</w>
reac tions</w>
therap y,</w>
initi al</w>
On e</w>
pro l
ag e,</w>
rel ationshi
previ ous</w>
- related</w>
ana esthe
saf ety</w>
op io
su ff
sp ective</w>
fact or</w>
as pir
i g
effect s.</w>
ne g
s it
comb ined</w>
ab out</w>
t op
mo der
str ic
li ke
( 5
t y-
th resh
ro w
os ine</w>
ocyt open
discontinu ation</w>
is on</w>
ay ed</w>
le ast</w>
d ar
in divid
d -
conside red</w>
a ver
per sist
te d.</w>
m an</w>
li p
in tr
glomer ular</w>
cum ul
pos sib
oc ic
ob arbit
inter val</w>
ur ing</w>
func tion.</w>
pre gn
pac litax
mark ed</w>
behavi oral</w>
bas ed</w>
rang e</w>
l ym
c an
1 6</w>
par t
on d
the sis</w>
t en</w>
resul t</w>
al ine</w>
ure ,</w>
ro lim
ineph rine</w>
determin ed</w>
ag e.</w>
expos ed</w>
regi on
oc hem
mil d</w>
my o
c ent</w>
inhibit or</w>
f ree</w>
(2 )</w>
at h</w>
er y
adul t</w>
prot ective</w>
pilocar p
ell ular</w>
al s.</w>
sever ity</w>
p tion</w>
i di
g ast
evalu ate</w>
s co
high -dose</w>
cor rel
con fir
atri al</w>
in o
I V</w>
ner ve</w>
descri be</w>
demon st
v s.</w>
diab etic</w>
) ;</w>
pat ter
ap pea
ang i
activ ation</w>
P A</w>
the y</w>
impro ved</w>
epilep tic
cont rib
diag nos
b le</w>
mor t
AN D</w>
tim es</w>
rati o</w>
phen y
oph yl
haloperid ol</w>
az epam</w>
catalep sy</w>
a sis</w>
the tic</w>
pa ren
e very</w>
anal gesi
suggest s</w>
I S
en d</w>
b io
thromb ocytopen
ch loro
ex er
( L
( -
zap ine</w>
ri pt
or g
inter sti
heal th
b ro
am in</w>
d r
1 7
requ ired</w>
st e
sen s
C a
1 3</w>
revie w</w>
ol ,</w>
re tro
y n
ob tained</w>
con tra
1 5
re action</w>
im en
s h
re x
rat ory</w>
acet yl
disc us
ti zed</w>
me mb
ser oton
sul f
lym ph
ame ter
ic ill
de li
3 ,</w>
reas t</w>
i f</w>
f oc
complic ations</w>
um .</w>
2 00
t u
qu in
microgram s/
inc e</w>
0 ,</w>
ph yl
valu es</w>
lev o
1 8</w>
intersti tial</w>
M e
and /
D i
tre m
my e
m es
and/ or</w>
2 %</w>
y ro
ta k
de ath</w>
H y
obser v
invol ved</w>
ev ent
enzym e</w>
le sions</w>
io dar
rele ase</w>
ol .</w>
ment al</w>
all y,</w>
ate le
th en</w>
b reast</w>
suggest ed</w>
reco very</w>
n al</w>
fe at
1 %</w>
ri am
aly sis</w>
vi v
respon se
I V
monit or
com mon
y oun
tion s.</w>
it ing</w>
a m</w>
al ized</w>
se d.</w>
day s.</w>
al though</w>
t -
s k
e pt
E x
pl atin</w>
glyc er
b ind
ag es</w>
1 8
val pro
like ly</w>
oly tic</w>
hor mon
sign s</w>
l y.</w>
azep ine</w>
y st
l u
P ark
O n</w>
( 6
sy m
ma z
mo di
bu pivaca
nerv ous</w>
mis sion</w>
epilep tic</w>
complic ation</w>
activ ity.</w>
phen yl
mi ght</w>
i or</w>
per it
Ac ute</w>
ve ,</w>
rema ined</w>
ati vely</w>
alph a</w>
st ,</w>
ocic ep
rever sible</w>
go ing</w>
Park in
D O
n or
enh anced</w>
be ing</w>
use .</w>
sm all</w>
ro ph
( B
ri tis</w>
lo x
ic in-induced</w>
P h
A L
k g</w>
C O
wei gh
adv anced</w>
m ou
P -
1 6
tum or</w>
loc al</w>
H g
man if
en ing</w>
P T
C lin
D )</w>
tissu e</w>
p ur
e t</w>
brady cardia</w>
p ec
le .</w>
ex pl
ery th
3 %</w>
B oth</w>
ot ens
an ne
abnormal ities</w>
ve d.</w>
relationshi p</w>
ref le
pro per
pl atele
b ene
kidne y</w>
col l
as s</w>
prop ran
def ici
syst olic</w>
morph ine</w>
R )</w>
pro ce
. ,</w>
ven tion</w>
pilocar pine</w>
con duc
adren ergic</w>
seizures .</w>
hyperal gesia</w>
health y</w>
c op
W he
ser ious</w>
ac hi
ad ju
ex trac
vol um
te red</w>
i ratory</w>
or atory</w>
N S
v es</w>
mye lo
appea red</w>
st atis
par ameter
g row
do es</w>
me mor
creat inine</w>
addi tion,</w>
f -
di g
character is
tro ph
perit one
na use
desc ribed</w>
co ag
ation al</w>
r he
Th e
test ed</w>
ri l</w>
group ,</w>
re .</w>
min im
eth yl
a thi
tem por
re main
memb ran
me d
ca uses</w>
ox if
g ran
cumul ative</w>
ation s,</w>
( 7
A -
pot assi
resp iratory</w>
glut am
transi ent</w>
multi ple</w>
me ta
drug .</w>
ch anne
asses s
si a.</w>
vit amin</w>
o path
O f</w>
tub ular</w>
ri st
reco gn
minut es</w>
st ained</w>
investig ate</w>
week s.</w>
r ing</w>
graph ic</w>
con ver
coca ine-
m uc
de pres
ab dom
theli al</w>
occur rence</w>
hydrox y
um ,</w>
ev o
direc t</w>
19 9
( 8
cut aneous</w>
aff ected</w>
m ed</w>
cont aining</w>
re d.</w>
vari ous</w>
spont aneous</w>
ot yp
ex hib
n al
f r
ay s</w>
ab il
for m</w>
contr ast</w>
S E</w>
or s
par tial</w>
occ ur</w>
injec tions</w>
convul sions</w>
c y</w>
mg/m 2</w>
prev ented</w>
continu ous</w>
anesthe sia</w>
vas cul
rel ative</w>
med ical</w>
ap am
ag ed</w>
re p
manif est
bloc k</w>
0.05 ).</w>
ex ten
impro vement</w>
ri al</w>
pro v
pro duce</w>
de ath
chol in
ar th
a i
D uring</w>
( R
sho w</w>
in s</w>
identi fied</w>
H g</w>
r are</w>
l ,</w>
immun o
angi otens
C B
i.v .</w>
ei ght</w>
Parkin son
prev ent</w>
pres c
poin t
t ent</w>
